Research
October 15, 2024
UAMS Establishes Proteomics Center of Excellence in Little Rock with Thermo Fisher Scientific
The University of Arkansas for Medical Sciences (UAMS) announced the launch of the Thermo Fisher Scientific Center of Excellence for Proteomics at UAMS — the first and only academic-industry partnership of its kind in the United States. The world leader in serving science, Thermo Fisher Scientific, entered into a formal agreement with the IDeA National…
October 14, 2024
Symposium Showcases Promising Research Aimed at Reducing Cancer Therapy Side Effects
What is worse? Cancer or cancer treatment? Ask any patient treated with chemotherapy, and the answer may be the treatment. Common side effects of chemotherapy include pain, fatigue, hair loss, mouth sores, bowel issues as well as nerve, muscle, cell and organ damage. And that’s just chemotherapy. Conventional X-ray radiation, a treatment needed by half…
October 8, 2024
Marius Nagalo, Ph.D., First at UAMS to Receive NIH New Innovator Award
LITTLE ROCK — A researcher at the Winthrop P Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS), Marius Nagalo, Ph.D., has received the prestigious New Innovator Award from the National Institutes of Health (NIH).
July 25, 2024
UAMS’ Michael Birrer, M.D., Ph.D., Publishes Study Results in JAMA Oncology on Treatment for Incurable Cervical Cancer
The results of an international clinical trial led by Michael Birrer, M.D., Ph.D., director of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS), on the use of a novel bispecific antibody for women with recurrent or metastatic cervical cancer were published today in JAMA Oncology. Cervical cancer is…
June 27, 2024
UAMS Winthrop P. Rockefeller Cancer Institute Awarded Five New Grants from National Cancer Institute
Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) have been awarded five new grants from the National Cancer Institute (NCI) in 2024, totaling $4.6 million. New grants include: $3.3 million NCI grant to create a Melanoma Resistance Evolution Atlas, Principal Investigator: Alan Tackett, Ph.D., Winthrop P….
May 31, 2024
Cancer Institute Research Retreat Focuses on Prevention, Early Detection
The third UAMS Winthrop P. Rockefeller Cancer Institute Cancer Research Retreat brought together more than 250 UAMS cancer researchers and faculty to share ongoing research on the prevention and early detection of cancer in Arkansas. An alarming statistic prompted the retreat’s prevention and early detection focus in the hopes that collaboration and sharing innovative strategies…
April 2, 2024
Distinguished Cancer Researcher, Yong Zhu, Ph.D., Joins UAMS Winthrop P. Rockefeller Cancer Institute Leadership
Prominent cancer epidemiologist, Yong Zhu, Ph.D., has joined the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute as associate director for population science and translational science. He also holds an appointment as professor of epidemiology in the UAMS Fay W. Boozman College of Public Health. Zhu joins UAMS after serving for…
March 26, 2024
UAMS Awarded $11.48 Million Federal Grant to Establish Center for Molecular Interactions in Cancer
The University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute received a five-year, $11.48 million federal grant to create the Center for Molecular Interactions in Cancer (CMIC). The grant was awarded by the National Institute of General Medical Sciences (NIGMS) Centers of Biomedical Research Excellence (COBRE) program. COBRE grants are awarded to…
January 19, 2024
Arkansan Sees Advanced Cancer Disappear with Experimental Drug Offered at UAMS Winthrop P. Rockefeller Cancer Institute
A Little Rock man with resistant kidney cancer who underwent experimental immunotherapy in Phase 1 Clinical Trials at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute has experienced a complete remission.
December 15, 2023
UAMS Myeloma Researcher Sees‘ Impressive’ Results in Clinical Trials of Bispecific Antibody Treatments
Many patients at the UAMS Myeloma Center have relapsed refractory myeloma, meaning they have nearly run out of effective treatment options. Fortunately, the center has talented clinical researchers like Carolina Schinke, M.D., with access to the latest medications, including promising study drugs. Schinke is leading a clinical trial at UAMS of a promising new bispecific…
Next page